Fulcrum Therapeutics Inc
1 day chart
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company’s clinical product candidate, losmapimod, is developed for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Its other clinical product candidate is FTX-6058, which is developed for the treatment of certain hemoglobinopathies, including sickle cell disease (SCD). The Company has developed a product engine to identify and validate cellular drug targets that can modulate gene expression to treat known root causes of genetically defined diseases. The Company’s product engine integrates patient-derived tissue and disease-relevant cell models that it interrogates using its pharmacologically diverse and annotated small-molecule compound library and customized CRISPR and RNAi libraries.
Buy US stocks in Australia starting with FULC. Open an account and start investing today!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in FULC
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.